Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Core Insights - Lisata Therapeutics and Valo Therapeutics have initiated a preclinical research collaboration to explore the combination of Lisata's certepetide and ValoTx's PeptiCRAd platform technology in melanoma treatment [1][2] - The collaboration aims to enhance patient outcomes by addressing challenges in current melanoma therapies, such as resistance and metastasis [2] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [4] - Certepetide, Lisata's investigational drug, selectively activates a transport mechanism to improve the delivery of anti-cancer agents to tumors and modifies the tumor microenvironment [3][4] - Certepetide has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers, indicating its potential in treating serious conditions [3] Valo Therapeutics Overview - Valo Therapeutics is an immunotherapy company developing tumor antigen-coated replication-competent viruses as therapeutic vaccines against cancer [6] - The PeptiCRAd platform is designed to activate the tumor microenvironment and elicit broad immune responses against multiple tumor antigens [5][6] - ValoTx's lead product, PeptiCRAd-1, is currently in Phase 1 clinical testing for various cancers, including melanoma [5]